Showing results (71-80 of 146) with videos related to

Sort By:
Pageof 15
Neurology|March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based StudyTim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Neurological Research|May 2, 2025
Clinical characteristics and prognostic clinical factors of anti-gamma-aminobutyric acid-B receptor (GABAB-R) encephalitis in Türkiye: a multicenter studyRabia Gokcen Gozubatik-Celik, Betul Baykan, Ahmed Serkan Emekli, et al.
JAMA Neurology|July 28, 2020
Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple SclerosisNathaniel Lizak, Charles B Malpas, Sifat Sharmin, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 27, 2024
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBaseTim Spelman, Sara Eichau, Raed Alroughani, et al.
Multiple Sclerosis and Related Disorders|June 26, 2025
Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad StudyMeryem Tuba Sönmez, Mehmet Fatih Yetkin, Duygu Arslan Mehdiyev, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Risk of secondary progressive multiple sclerosis after early worsening of disabilityWinston Dzau, Sifat Sharmin, Francesco Patti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practiceTim Spelman, Claire Meyniel, Juan Ignacio Rojas, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2023
Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS studyMikael Cohen, Océane Thomel-Rocchi, Aksel Siva, et al.
Pageof 15